Effect of (R)-salsolinol and N-methyl-(R)-salsolinol on the balance impairment between dopamine and acetylcholine in rat brain: Involvement in pathogenesis of Parkinson disease

Clinical Chemistry

Volumn 54, Issue 4, 2008, Pages 705-712

  Zhu, Wei ^a   Wang, Dan ^a   Zheng, Jiaohong ^a   An, Yarui ^a   Wang, Qingjiang ^a   Zhang, Wen ^a   Jin, Litong ^a   Gao, Hongying ^a   Lin, Longnian ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ACETYLCHOLINESTERASE; DOPAMINE; SALSOLINE; SALSOLINOL; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ISOQUINOLINE DERIVATIVE; N METHYLSALSOLINIUM; N-METHYLSALSOLINIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BALANCE IMPAIRMENT; CONTROLLED STUDY; DRUG EFFECT; ELECTROCHEMICAL DETECTION; ENZYME ACTIVITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; RAT; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; CHEMISTRY; ELECTROCHEMISTRY; METABOLISM; MICRODIALYSIS; SPRAGUE DAWLEY RAT; STEREOISOMERISM;

RATTUS;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACETYLCHOLINE; ACETYLCHOLINESTERASE; ANIMALS; BRAIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOPAMINE; ELECTROCHEMISTRY; ISOQUINOLINES; MALE; MICRODIALYSIS; PARKINSON DISEASE, SECONDARY; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM;

EID: 42449095525     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2007.097725     Document Type: Article

References (36)

1. Goetz CG. Charcot and Parkinson's disease. In: Factor S, Weiner W, eds. Parkinson's Disease Diagnosis and Clinical Management. New York: Demos Medical Publishing, 2002; 19 p.
2. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (Wash DC) 1983;219:979-80.
3. Naoi M, Maruyama W, Dostert P, Kohda K, Kaiya T. A novel enzyme enantio-selectively synthesizes (R)salsolinol, a precursor of a dopaminergic neurotoxin, N-methyl(R)salsolinol. Neurosci Lett 1996;212:183-6.
4. Maruyama W, Nakahara D, Ota M, Takahashi T, Takahashi A, Naqatsu T, Naoi M. N-Methylation of dopamine-derived 6,7-dihydroxy-1,2,3,4- tetrahydroisoquinoline, (R)-salsolinol, in rat brains: in vivo microdialysis study. J Neurochem 1992;59:395-400.
5. Naoi M, Maruyama W, Zhang JH, Takahashi T, Deng Y, Dostert P. Enzymatic oxidation of the dopaminergic neurotoxin, 1(R),2(N)-dimethyl-6,7- dihydroxy-1,2,3,4-tetrahydroisoquinoline, into 1,2(N)-dimethyl-6,7- dihydroxyisoquinolinium ion. Life Sci 1995;57:1061-6.
6. Maruyama W, Dostert P, Matsubara K, Naoi M. N-methyl(R) salsolinol produces hydroxyl radicals: involvement to neurotoxicity. Free Radic Biol Med 1995;19:67-75.
7. Sandler M, Bonham Carter S, Hunter KR, Stern GM. Tetrahydroisoquinoline alkaloids: in vivo metabolites of L-DOPA in man. Nature (Lond) 1973;241:439-43.
8. Moser A, Kömpf D. Presence of methyl-6,7-dihydroxy-1,2,3,4- tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF. Life Sci 1992;50:1885-91.
9. Naoi M, Maruyama W, Dostert P, Hashizume Y, Nakahara D, Takahashi T, Ota M. Dopamine-derived endogenous (R),2(N)-dimethyl-6,7-dihydroxy-1, 2,3,4- tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res 1996;709:285-95.
10. Naoi M, Maruyama W, Akao Y, Yi H. Dopamine-derived endogenous N-methyl-(R)-salsolinol: its role in Parkinson's disease. Neurotoxicol Teratol 2002;24:579-91.
11. Poirier LJ, Sourkes TL. Influence of the substantia nigra on the catecholamine content of the striatum. Brain 1965;88:181-92.
12. Kaneko S, Hikida T, Watanabe D, Ichinose H, Nagatsu T, Kreitman RJ, et al. Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science (Wash DC) 2000;289:633-7.
13. Zhou FM, Liang Y, Dani JA. Endogenous nicotinic cholinergic activity regulates dopamine release in the striatum. Nat Neurosci 2001;4:1224-9.
14. Pisani A, Bonsi P, Centonze D, Calabresi P, Bernardi G. Activation of D2-like dopamine receptors reduces synaptic inputs to striatal cholinergic interneurons. J Neurosci 2000;20:RC69.
15. Soreq H, Seidman S. Acetylcholinesterase: new roles for an old actor. Nat Rev Neurosci 2001;2:294-302.
16. Lotti M. Cholinesterase inhibition: complexities in interpretation. Clin Chem 1995;41:1814-8.
17. Committee on Care and Use of Laboratory Animals. Guide for the Care and Use of Laboratory Animals. Washington, DC: Institute of Laboratory Animal Resources, National Research Council, 1985; 83 p.
18. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1998.
19. Li Y, Lin X. Simultaneous electroanalysis of dopamine, ascorbic acid and uric acid by poly (vinyl alcohol) covalently modified glassy carbon electrode. Sens Actuators B Chem 2006;115:134-9.
20. Zhang W, Cao XN, Xian YZ, Xu Q, Zhang S, Jin LT. New microdialysis- electrochemical device for simultaneous determination of ascorbic acid and 5-hydroxyindole-3-acetic acid in rat striatum. Anal Chim Acta 2002;458:337-44.
21. Mitchell KM. Acetylcholine and choline amperometric enzyme sensors characterized in vitro and in vivo. Anal Chem 2004;76:1098-106.
22. Inoue T, Kirchhoff JR, Hudson RA. Enhanced measurement stability and selectivity for choline and acetylcholine by capillary electrophoresis with electrochemical detection at a covalently linked enzyme-modified electrode. Anal Chem 2002;74:5321-6.
23. Ellman GL, Courtney KD, Andres V Jr, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961;7:88-90.
24. Freitas RM, Sousa FCF, Viana GSB, Fonteles MMF. Acetylcholinesterase activities in hippocampus, frontal cortex and striatum of Wistar rats after pilocarpine-induced status epilepticus. Neurosci Lett 2006;399:76-8.
25. Huang T, Yang L, Gitzen J, Kissinger PT, Vreeke M, Heller A. Detection of basal acetylcholine in rat brain microdialysate. J Chromatogr B Biomed Appl 1995;670:323-7.
26. Maruyama W, Dostert P, Naoi M. Dopamine-derived 1-methyl-6,7- dihydroxyisoquinolines as hydroxyl radical promoters and scavengers in the rat brain: in vivo and in vitro studies. J Neurochem 1995;64:2635-43.
27. Hashitani T, Mizukawa K, Kumazaki M, Nishino H. Dopamine metabolism in the striatum of hemiparkinsonian model rats with dopaminergic grafts. Neurosci Res 1998;30:43-52.
28. Calabresi P, Picconi B, Parnetti L, Filippo MD. A convergent model for cognitive dysfunction in Parkinson's disease: the critical dopamine- acetylcholine synaptic balance. Lancet Neurol 2006;5:974-83.
29. Burnhan WM. Drugs acting on the basal ganglia. In: Principles of Medical Pharmacology. Toronto, Philadelphia: B.C. Decker Inc., 1989; 198 p.
30. Dougherty DA, Stauffer DA. Acetylcholine binding by a synthetic receptor: implications for biological recognition. Science (Wash DC) 1990;250:1558-60.
31. Wyse ATS, Stefanello FM, Chiarani F, Delwing D, Wannmacher CMD, Wajner M. Arginine administration decreases cerebral cortex acetylcholinesterase and serum butyrylcholinesterase probably by oxidative stress induction. Neurochem Res 2004;29:385-9.
32. Buyukokuroglu ME, Cemek M, Yurumez Y, Yavuz Y, Aslan A. Antioxidative role of melatonin in organophosphate toxicity in rats. DOI# 10.1007/s10565-007- 9024-z (accessed December 2007).
33. Tsakiris S, Angelogianni P, Schulpis KH, Stavridis JC. Protective effect of L-phenylalanine on rat brain acetylcholinesterase inhibition induced by free radicals. Clin Biochem 2000;33:103-6.
34. Ceravolo R, Volterrani D, Frosini D, Bernardini S, Rossi C, Logi C, et al. Brain perfusion effects of cholinesterase inhibitors in Parkinson's disease with dementia. J Neural Transm 2006;113:1787-90.
35. Sirviö J, Rinne JO, Valjakka A, Rinne UK, Riekkinen PJ, Paljärvi L. Different forms of brain acetylcholinesterase and muscarinic binding in Parkinson's disease. J Neurol Sci 1989;90:23-32.
36. Stephenson J. Exposure to home pesticides linked to Parkinson disease. JAMA 2000;283:3055-6.